BioLineRx Ltd. (BLRX)

NASDAQ: BLRX · IEX Real-Time Price · USD
1.120
+0.010 (0.90%)
At close: Mar 28, 2024, 4:00 PM
1.100
-0.020 (-1.79%)
After-hours: Mar 28, 2024, 6:21 PM EDT

Total Valuation

BioLineRx has a market cap or net worth of $82.69 million. The enterprise value is $51.28 million.

Market Cap 82.69M
Enterprise Value 51.28M

Important Dates

The last earnings date was Tuesday, March 26, 2024, before market open.

Earnings Date Mar 26, 2024
Ex-Dividend Date n/a

Share Statistics

BioLineRx has 78.04 million shares outstanding.

Shares Outstanding 78.04M
Owned by Insiders (%) 9.43%
Owned by Institutions (%) 1.67%
Float n/a

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 17.23
Forward PS n/a
PB Ratio 6.25
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 10.68
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.88.

Current Ratio 1.53
Quick Ratio 1.43
Debt / Equity 0.88
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -26.95

Financial Efficiency

Return on equity (ROE) is -280.20% and return on invested capital (ROIC) is -200.27%.

Return on Equity (ROE) -280.20%
Return on Assets (ROA) -99.20%
Return on Capital (ROIC) -200.27%
Revenue Per Employee $97,959
Profits Per Employee -$1.24M
Employee Count 49
Asset Turnover 0.08
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +30.23% in the last 52 weeks. The beta is 0.93, so BioLineRx's price volatility has been similar to the market average.

Beta (1Y) 0.93
52-Week Price Change +30.23%
50-Day Moving Average 1.21
200-Day Moving Average 1.51
Relative Strength Index (RSI) 44.55
Average Volume (30 Days) 322,329

Short Selling Information

Short Interest 324,649
Short Previous Month 183,915
Short % of Shares Out 0.45%
Short % of Float n/a
Short Ratio (days to cover) 0.61

Income Statement

In the last 12 months, BioLineRx had revenue of $4.80 million and -$60.61 million in losses. Loss per share was -$0.06.

Revenue 4.80M
Gross Profit 1.11M
Operating Income -49.69M
Pretax Income -60.61M
Net Income -60.61M
EBITDA -57.06M
EBIT -58.45M
Loss Per Share -$0.06
Full Income Statement

Balance Sheet

The company has $42.99 million in cash and $11.59 million in debt, giving a net cash position of $31.40 million or $0.40 per share.

Cash & Cash Equivalents 42.99M
Total Debt 11.59M
Net Cash 31.40M
Net Cash Per Share $0.40
Equity / Book Value 13.22M
Book Value Per Share 0.17
Working Capital 16.33M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$22.61 million and capital expenditures -$116,000, giving a free cash flow of -$22.72 million.

Operating Cash Flow -22.61M
Capital Expenditures -116,000
Free Cash Flow -22.72M
FCF Per Share -$0.35
Full Cash Flow Statement

Margins

Gross margin is 23.08%, with operating and profit margins of -1,035.29% and -1,262.79%.

Gross Margin 23.08%
Operating Margin -1,035.29%
Pretax Margin -1,262.79%
Profit Margin -1,262.79%
EBITDA Margin -1,188.77%
EBIT Margin -1,217.60%
FCF Margin -473.42%

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -24.47%
Shareholder Yield -24.47%
Earnings Yield -73.31%
FCF Yield -27.48%

Analyst Forecast

The average price target for BioLineRx is $12.50, which is 1,016.07% higher than the current price. The consensus rating is "Strong Buy".

Price Target $12.50
Price Target Difference 1,016.07%
Analyst Consensus Strong Buy
Analyst Count 2
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on July 15, 2019. It was a reverse split with a ratio of 1:15.

Last Split Date Jul 15, 2019
Split Type Reverse
Split Ratio 1:15

Scores

BioLineRx has an Altman Z-Score of -10.21 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -10.21
Piotroski F-Score 2